Evidence map›Paper›PMID 42286339›Full record

ArticleNature cancer2026

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Jack Y Ghannam, Julian Bryan, Jakob Weiss, Daniel Kovarsky, David Merrell, Conor Messer, Kristy Schlueter-Kuck, Geoffrey G Fell, Mary Jane Lim-Fat, Gilbert Youssef and 20 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Jack Y Ghannam *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0275-9099
Julian Bryan *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jakob Weiss *Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3879-0568
Daniel Kovarsky *Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
David Merrell *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Conor MesserBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kristy Schlueter-KuckBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Geoffrey G FellDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Mary Jane Lim-FatDivision of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Gilbert YoussefHarvard Medical School, Boston, MA, USA.
Rifaquat RahmanDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
Lei QinDepartment of Imaging, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.
Geoffrey S YoungDepartments of Radiology, Mass General Brigham, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8213-865X
J Thomas JanesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0007-0887-8482
McKayla Van OrdenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0008-6831-4707
Kathleen L PfaffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew GansCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0002-6650-380X
Emma S LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0005-0560-2849
Raymond Y HuangDepartments of Radiology, Mass General Brigham, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.
Brian P DanyshBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6839-6337
Laxmi ParidaIBM Research, Yorktown Heights, NY, USA.ORCID http://orcid.org/0000-0002-7872-5074
Shuqiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9106-6141
Patrick Y WenCenter for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0774-7700
E Antonio ChioccaCenter for Tumors of the Nervous System, Mass General Brigham Cancer Institute & Department of Neurosurgery, Mass General Brigham, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5183-1670
Donna NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2566-3145
Keith L LigonBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7733-600X
Itay TiroshDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
David A ReardonCenter for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6674-0157
Gad GetzHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0936-0753
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. catherine_wu@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-3348-5054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42286339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.